Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 14/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | CALCA | P06881 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12050420 | 0.80 | CALCRL (0.64) | CALCRLCALCA | |
| SCHEMBL12050619 | 0.79 | CALCRL (0.54) | CALCRLCALCA | |
| SCHEMBL12050163 | 0.78 | CALCRL (0.54) | CALCRLCALCA | |
| SCHEMBL12050415 | 0.77 | CALCRL (0.61) | CALCRLCALCA | |
| SCHEMBL12050171 | 0.77 | CALCRL (0.53) | CALCRLCALCA | |
| SCHEMBL12990254 | 0.76 | CALCA (0.45) | CALCRLPIK3CBPIK3CDCALCA | |
| SCHEMBL12060842 | 0.76 | CALCRL (0.55) | CALCRLCALCA | |
| SCHEMBL12050418 | 0.76 | CALCRL (0.57) | CALCRLCALCA | |
| SCHEMBL12050423 | 0.76 | CALCRL (0.64) | CALCRLCALCALMNA | |
| SCHEMBL12061379 | 0.74 | CALCRL (0.53) | CALCRLCALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071770-B2 | Spirohydantoin aryl CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071770-B2 | Spirohydantoin aryl CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20090239870-A1 | Spirohydantoin Aryl Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090239870-A1 | Spirohydantoin Aryl Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| WO-2007061676-A2 | SPIROHYDANTOIN ARYL CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239870-A1 | Spirohydantoin Aryl Cgrp Receptor Antagonists | BDKRB1, BDKRB2, CALCRL | CALCRL 3/4885PIK3CB 4750/4885PIK3CD 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.